Bryan J. McMichael - 13 Jun 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Title: Executive Vice President, Accounting, Corporate Controller and Principal Accounting Officer
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Bryan J. McMichael
Issuer symbol
CHRS
Transactions as of
13 Jun 2023
Net transactions value
$0
Form type
4
Filing time
15 Jun 2023, 16:41:15 UTC
Previous filing
29 Mar 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +30,000 $0.000000 30,000 13 Jun 2023 Common Stock 30,000 $5.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 50% of the shares on each anniversary measured from June 13, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

Title: Executive Vice President, Accounting, Corporate Controller and Principal Accounting Officer